GlassScriptPhysician profile
Josiah Bote
NPI 1952763997
$1,716.78
in general payments reported to CMS, 2019-2025
23 companies · $598 in 2025
The $598 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $91.53 · 2020: $193 · 2021: $159 · 2023: $44.34 · 2024: $632 · 2025: $598.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,274.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,273.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $290.85 | 2021-2024 | Thoratec Heartmate 3 Lvas Implant Kit |
| Novartis Pharmaceuticals Corporation | $156.65 | 2024-2025 | |
| Amgen INC. | $146.32 | 2024-2025 | Repatha, Repatha |
| Amarin Pharma, INC. | $143.53 | 2019-2020 | |
| Pfizer INC. | $116.64 | 2025 | |
| Novo Nordisk INC | $106.82 | 2024-2025 | Wegovy, Ozempic |
| Boston Scientific Corporation | $97.41 | 2024-2025 | Watchman Flx, Cds - Mct/Cem Monitoring |
| Astrazeneca Pharmaceuticals LP | $96.10 | 2023-2025 | Farxiga, Wainua |
| Janssen Pharmaceuticals, INC | $85.15 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $83.74 | 2019-2025 | Eliquis, Camzyos |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $66.35 | 2019-2021 | |
| Kestra Medical Technology Services, INC. | $49.95 | 2025 | Assure Wcd |
| Kiniksa Pharmaceuticals International, Plc | $44.45 | 2024 | Arcalyst |
| Merck Sharp & Dohme LLC | $41.10 | 2025 | Verquvo |
| Actelion Pharmaceuticals US, INC. | $36.90 | 2024-2025 | Uptravi, Opsumit |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $24.82 | 2025 | Nexletol |
| Edwards Lifesciences Corporation | $23.40 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Csl Behring | $23.22 | 2020 | |
| Abiomed | $20.89 | 2024 | Impella |
| Silk Road Medical, INC. | $16.82 | 2024 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.19 | 2024 | Jardiance |
| W. L. Gore & Associates, INC. | $15.09 | 2025 | Gore Cardioform Septal Occluder |
| Altathera Pharmaceuticals LLC | $14.39 | 2024 | Sotalol Hydrochloride |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Josiah Bote listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.